30 years of Novartis, powered by 250 years of innovation
Rooted in a legacy of scientific discovery, Novartis continues to advance breakthrough medicines that redefine the future of care for patients.
Latest news
Europe Is Losing the Pharma Investment Race – But the Comeback Is Within Reach: An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
Novartis Financial Results – Q2 2026
Novartis announces the company’s financial results for the second quarter and first half of 2026.
Annual reporting suite
Explore and download our Annual Report 2025, Report on Nonfinancial Matters 2025 and other reporting documents.